[{"id":6088,"regimens":[{"id":11483,"duration":{"id":5538,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7165,"name":"Darunavir","url":"cure-api2.ncats.io/v1/drugs/7165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8100,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11483},{"id":8101,"answer":"In a novel combination with another drug","answer_other":"","regimen":11483}],"created":"2020-09-24T17:47:39.762480Z","updated":"2020-12-17T20:13:53.761893Z","dose":"600 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6088},{"id":11484,"duration":{"id":5539,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10164,"name":"Ritonavir","url":"cure-api2.ncats.io/v1/drugs/10164","rxNorm_id":null,"notes":null},"use_drug":[{"id":8169,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11484},{"id":8170,"answer":"In a novel combination with another drug","answer_other":"","regimen":11484}],"created":"2020-09-24T17:47:39.770463Z","updated":"2020-12-17T20:13:53.768445Z","dose":"100 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6088},{"id":11485,"duration":{"id":5540,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8171,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11485},{"id":8172,"answer":"In a novel combination with another drug","answer_other":"","regimen":11485}],"created":"2020-09-24T17:47:39.776501Z","updated":"2020-12-17T20:13:53.773934Z","dose":"400 mg","frequency":"OD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6088},{"id":11486,"duration":{"id":5541,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8173,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11486},{"id":8174,"answer":"In a novel combination with another drug","answer_other":"","regimen":11486}],"created":"2020-09-24T17:47:39.782617Z","updated":"2020-12-17T20:13:53.779733Z","dose":"loading dose of 1600 mg orally every 12 h, followed by 600 mg orally every 8 h","frequency":"TDS","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6088},{"id":11487,"duration":{"id":5542,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9593,"name":"Peginterferon Alfa-2A","url":"cure-api2.ncats.io/v1/drugs/9593","rxNorm_id":null,"notes":null},"use_drug":[{"id":8175,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11487},{"id":8176,"answer":"In a novel combination with another drug","answer_other":"","regimen":11487}],"created":"2020-09-24T17:47:39.788562Z","updated":"2020-12-17T20:13:53.811309Z","dose":"180 μg","frequency":"single dose","route":"subcutaneously","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6088}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8023,"answer":"Imaging","answer_other":"","report":6088},{"id":8024,"answer":"PCR","answer_other":"","report":6088},{"id":8025,"answer":"Clinical assessment","answer_other":"","report":6088}],"how_diagnosis":[{"id":13602,"answer":"Clinical assessment","answer_other":"","report":6088},{"id":13603,"answer":"Imaging","answer_other":"","report":6088},{"id":13604,"answer":"PCR","answer_other":"","report":6088}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4079,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6088},{"id":4080,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6088}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":336,"answer":"White","answer_other":""}],"created":"2020-09-24T17:44:37.657208Z","updated":"2020-12-17T20:13:53.754280Z","title":"Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32483527,"doi":"10.1016/j.idcr.2020.e00837","article_url":"https://pubmed.ncbi.nlm.nih.gov/32483527/","pub_year":2020,"published_authors":"El-Lababidi RM\r\nMooty M\r\nBonilla MF\r\nSalem NM","article_author_email":"Author email could not be found.","journal":"IDCases","abstract":"The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.          \r\n        Keywords:      \r\n                  Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"A sputum culture with gram stain as well as methicillin-resistant S. aureus nasal swab were collected, and an empiric antibacterial regimen of cefepime and intravenous vancomycin was initiated to cover a possible hospital-acquired pneumonia.\r\nCefepime and vancomycin were de-escalated to amoxicillin-clavulanate when sputum culture showed growth of normal oral flora and the MRSA nasal swab was negative.\r\nFavipiravir was added to his regimen at a loading dose of 1600 mg orally every 12 h, followed by 600 mg orally every 8 h, and hydroxychloroquine was discontinued.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7165,11165,8342,9593,10164]},{"id":6114,"regimens":[{"id":11541,"duration":{"id":5593,"approximate_duration":"10 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8186,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11541},{"id":8187,"answer":"In a novel combination with another drug","answer_other":"","regimen":11541}],"created":"2020-09-25T19:01:11.646891Z","updated":"2020-09-25T19:12:08.418940Z","dose":"400 mg","frequency":"OD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6114},{"id":11542,"duration":{"id":5594,"approximate_duration":"10 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8188,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11542},{"id":8189,"answer":"In a novel combination with another drug","answer_other":"","regimen":11542}],"created":"2020-09-25T19:01:11.654720Z","updated":"2020-09-25T19:12:08.425476Z","dose":"400 mg/100 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6114},{"id":11543,"duration":{"id":5595,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8190,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11543},{"id":8191,"answer":"In a novel combination with another drug","answer_other":"","regimen":11543}],"created":"2020-09-25T19:01:11.661069Z","updated":"2020-09-25T19:12:08.432279Z","dose":"1600 mg orally every 12 h followed by 600 mg orally every 8 h","frequency":"TDS","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6114},{"id":11544,"duration":{"id":5596,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9593,"name":"Peginterferon Alfa-2A","url":"cure-api2.ncats.io/v1/drugs/9593","rxNorm_id":null,"notes":null},"use_drug":[{"id":8192,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11544},{"id":8193,"answer":"In a novel combination with another drug","answer_other":"","regimen":11544}],"created":"2020-09-25T19:01:11.667491Z","updated":"2020-09-25T19:12:08.438220Z","dose":"180 μg per week","frequency":"2 doses","route":"subcutaneously","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6114}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8026,"answer":"Clinical assessment","answer_other":"","report":6114},{"id":8027,"answer":"Imaging","answer_other":"","report":6114}],"how_diagnosis":[{"id":13649,"answer":"Clinical assessment","answer_other":"","report":6114},{"id":13650,"answer":"Imaging","answer_other":"","report":6114},{"id":13651,"answer":"PCR","answer_other":"","report":6114}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4107,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6114}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":354,"answer":"White","answer_other":""}],"created":"2020-09-25T18:58:43.113745Z","updated":"2020-09-25T19:12:08.410856Z","title":"Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32483527,"doi":"10.1016/j.idcr.2020.e00837","article_url":"https://pubmed.ncbi.nlm.nih.gov/32483527/","pub_year":2020,"published_authors":"El-Lababidi RM\r\nMooty M\r\nBonilla MF\r\nSalem NM","article_author_email":"Author email could not be found.","journal":"IDCases","abstract":"The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.          \r\n        Keywords:      \r\n                  Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient was initiated on empirical antibacterial therapy with azithromycin.\r\nHe was also started empirically on cefepime for possible hospital-acquired pneumonia, which was later de-escalated to amoxicillin-clavulanate when sputum cultures showed growth of normal oral flora.\r\nOxygen therapy +","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11165,8342,8783,9593]},{"id":6117,"regimens":[{"id":11549,"duration":{"id":5601,"approximate_duration":"10 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8194,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11549},{"id":8195,"answer":"In a novel combination with another drug","answer_other":"","regimen":11549}],"created":"2020-09-25T19:15:39.324542Z","updated":"2020-09-25T19:23:43.198352Z","dose":"400/100 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6117},{"id":11550,"duration":{"id":5602,"approximate_duration":"10 days","dates_unknown":true},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8196,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11550},{"id":8197,"answer":"In a novel combination with another drug","answer_other":"","regimen":11550}],"created":"2020-09-25T19:15:39.331850Z","updated":"2020-09-25T19:23:43.204529Z","dose":"1600 mg orally every 12 h followed by 600 mg orally every 8 h","frequency":"TDS","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6117},{"id":11551,"duration":{"id":5603,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9593,"name":"Peginterferon Alfa-2A","url":"cure-api2.ncats.io/v1/drugs/9593","rxNorm_id":null,"notes":null},"use_drug":[{"id":8198,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11551},{"id":8199,"answer":"In a novel combination with another drug","answer_other":"","regimen":11551}],"created":"2020-09-25T19:15:39.338155Z","updated":"2020-09-25T19:23:43.210213Z","dose":"180 μg per week","frequency":"2 doses","route":"Subcutaneously","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6117}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8028,"answer":"Clinical assessment","answer_other":"","report":6117},{"id":8029,"answer":"PCR","answer_other":"","report":6117}],"how_diagnosis":[{"id":13658,"answer":"Clinical assessment","answer_other":"","report":6117},{"id":13659,"answer":"Imaging","answer_other":"","report":6117},{"id":13660,"answer":"PCR","answer_other":"","report":6117}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4111,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6117}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":355,"answer":"White","answer_other":""}],"created":"2020-09-25T19:14:01.021019Z","updated":"2020-09-25T19:23:43.190853Z","title":"Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32483527,"doi":"10.1016/j.idcr.2020.e00837","article_url":"https://pubmed.ncbi.nlm.nih.gov/32483527/","pub_year":2020,"published_authors":"El-Lababidi RM\r\nMooty M\r\nBonilla MF\r\nSalem NM","article_author_email":"Author email could not be found.","journal":"IDCases","abstract":"The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.          \r\n        Keywords:      \r\n                  Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hyperlipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11165,8783,9593]}]